CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

By B. Savoldo, C. Ramos, E. Liu, M. Mims, M. Keating, G. Carrum, R. Kamble, C. Bollard, A. Gee, Z. Mei and 6 more. Journal of Clinical Investigation, 2011

993 citations recorded by the source corpus.

Subfields: Electrical and Electronic Engineering, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/49f4bbf2f67cb142126b14cd5809c9d36307bde8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Jennifer N. Brudno
2. J. Kochenderfer

In Oncology

1. J. Kochenderfer
2. Jennifer N. Brudno

Citations in the corpus

• Emerging trends and new developments in regenerative medicine: a scientometric update (2000 – 2014) (2014, background): “2011 CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients J CLIN INVEST [62]”
• Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management (2018, background): “CARs with costimulatory domains have increased efficacy compared to first-generation CARs [3,49,65].”
• Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. (2014, methodology): “Persistence of CAR-T cells was evaluated in peripheral blood at different time points after infusion by a specific quantitative polymerase chain reaction (qPCR) assay.(8)”